Helius Medical Technologies announced the first third-party reimbursement from a major insurance carrier for the Company’s Portable Neuromodulation Stimulator device. The reimbursed rate, net of a 7% rebate, results in pricing of $16,554 for the controller and $7,347 for the mouthpiece, exclusive of rounding.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HSDT:
- Helius Medical to exhibit at 2024 CMSC Annual Meeting
- Helius Medical Technologies to Exhibit at 2024 CMSC Annual Meeting, Marking a Year of Achievements: Making PoNS More Available to People with MS
- Helius Medical Technologies, Inc. Announces PoNS® Is Now Available on the Veterans Affairs (VA) Federal Supply Schedule (FSS) and General Services Administration (GSA) Advantage Contracts
- Helius Medical announces PoNS now available on VA FSS, GSA
- Helius Medical reports Q1 EPS ($3.08), consensus ($3.87)